🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in the EU / 2026-525888-40-00
Authorised Phase I

A PHASE I FIRST-IN-HUMAN, OPEN-LABEL, MULTICENTER STUDYTO INVESTIGATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY ANTITUMOR ACTIVITY OF SIM0505 IN ADULT PARTICIPANTS WITH ADVANCED SOLID TUMORS

2026-525888-40-00 · tracked via the Priya Life Science EU tracker
Sponsor
Nextcure Inc.
Sponsor type
Pharmaceutical company
Therapeutic area
Neoplasms
Decision date
09/09/2026
Enrollment target
95
Sites
Italy, Poland, France, Spain

Condition studied

Advanced solid tumors

Eligibility

Age group
18-64 years, 65+ years
Sex
Female
Official registry record

This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View 2026-525888-40-00 on CTIS ↗ ← All trials in the EU